2173 related articles for article (PubMed ID: 22285209)
21. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
22. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Shami PJ; Deininger M
Leukemia; 2012 Feb; 26(2):214-24. PubMed ID: 21844872
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
24. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
[TBL] [Abstract][Full Text] [Related]
26. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
[TBL] [Abstract][Full Text] [Related]
27. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Ault P
Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403
[TBL] [Abstract][Full Text] [Related]
28. Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Bauer S; Romvari E
Clin J Oncol Nurs; 2009 Oct; 13(5):523-34. PubMed ID: 19793709
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
30. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Kantarjian H; Shah NP; Hochhaus A; Cortes J; Shah S; Ayala M; Moiraghi B; Shen Z; Mayer J; Pasquini R; Nakamae H; Huguet F; Boqué C; Chuah C; Bleickardt E; Bradley-Garelik MB; Zhu C; Szatrowski T; Shapiro D; Baccarani M
N Engl J Med; 2010 Jun; 362(24):2260-70. PubMed ID: 20525995
[TBL] [Abstract][Full Text] [Related]
31. Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
Breccia M; Alimena G
BioDrugs; 2011 Jun; 25(3):147-57. PubMed ID: 21528941
[TBL] [Abstract][Full Text] [Related]
32. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
33. Management of Bcr-Abl-positive leukemias with dasatinib.
Hochhaus A
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Gore L; Kearns PR; de Martino ML; Lee ; De Souza CA; Bertrand Y; Hijiya N; Stork LC; Chung NG; Cardos RC; Saikia T; Fagioli F; Seo JJ; Landman-Parker J; Lancaster D; Place AE; Rabin KR; Sacchi M; Swanink R; Zwaan CM
J Clin Oncol; 2018 May; 36(13):1330-1338. PubMed ID: 29498925
[TBL] [Abstract][Full Text] [Related]
35. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
[TBL] [Abstract][Full Text] [Related]
36. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
[TBL] [Abstract][Full Text] [Related]
37. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
38. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
Crit Rev Oncol Hematol; 2012 May; 82(2):159-70. PubMed ID: 21565522
[TBL] [Abstract][Full Text] [Related]
39. Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Jabbour E; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S75-81. PubMed ID: 19254884
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Li J; Xu G; Yu S; He L; Guo L
J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]